

## LYL1 (lymphoblastic leukemia derived sequence 1)

### Identity

Hugo [LYL1](#)  
Location 19p13.2

### DNA/RNA

Note DNA size: 3.83 kb; mRNA size: 1492 bp; Exons: 4.



Description Location of the LYL1 gene, identified by Non-random chromosomal translocation t(7;19)(q35;p13) associated with T-cell acute lymphoblastic leukemia (T-ALL), was mapped to the short arm of chromosome 19 (19p13) by in situ hybridization.

Transcription Expression levels of LYL1 are comparatively higher in normal bone marrow, spleen, lung, thymus and spinal cord tissues. Ectopic transcription is observed in T-lymphoblastic and myeloblastic leukemic cells.

### Protein

Description LYL1 encodes a basic helix-loop-helix (bHLH) protein, with 267 amino acids and molecular weight of 28628 Da.

Localisation Subcellular location is potentially intracellular (nucleus). However, ectopic protein staining was observed in cytoplasm of myeloid leukemia cells with immunohistochemistry.

Function Recent studies show that LYL1 is required for fetal and adult hematopoietic stem cell function and B-cell differentiation. Overexpression of LYL1 is implicated in the pathogenesis of T-ALL as well as myeloid malignancies (see below, disease implications). The LYL1 protein is a transcription factor (TF), structurally and functionally similar to another bHLH protein TAL1/SCL which is also implicated in T-ALL. Expression of both LYL1 and [TAL1/SCL](#) are regulated by the Ets and GATA factors; However, ectopic expression of SCL but not Lyl1 can rescue haematopoietic differentiation in SCL(-/-) ES-cells, providing a molecular explanation for the vastly different phenotypes of SCL(-/-) and Lyl1(-/-) mouse embryos. Efficient DNA binding of LYL1 requires dimerization with proteins. Specific in vivo association was observed between the bHLH and LIM proteins (LMO1 and [LMO2](#)). LYL1 readily forms heterodimeric complexes with [E2A](#) and may function as a dominant-negative preventing the activation of E2A responsive genes. LYL1 interacts also with [p105](#) the precursor of NF-KappaB1 p50.

Homology The bHLH region of LYL1 and TAL1/SCL proteins show 82% amino acid identity, suggesting that these two proteins share at least some target genes and biologic functions. However, LYL-1 and TAL1 diverge largely outside the bHLH region and display a distinct expression pattern in hematopoietic cells. Mouse Lyl-1 protein is 78% identical to human LYL1.

### Implicated in

Entity [t\(7;19\)\(q35;p13\)](#) --> [TCRB/LYL1](#) in T-cell acute lymphoblastic leukemia, other T-ALL, [acute myeloblastic leukemia](#) (AML) or myelodysplastic syndrome (MDS)

Disease The LYL1 gene was originally identified at the chromosomal translocation

t(7;19)(q35;p13) associated with T-ALL. However, over-expression of LYL1 has been reported in T-ALL cases without apparent chromosome aberration. Recent studies on leukemia cell lines and patient samples suggested its involvement in myeloid malignancies. Using real-time quantitative RT-PCR assay, the authors found that the expression of LYL1 was at a significantly higher level than normal bone marrow cells in the majority of cases of acute myeloblastic leukemia (AML) or myelodysplastic syndrome when compared to normal bone marrow. This study also showed that LYL1 was highly expressed in most AML cell lines and in CD34(+) AML cells.

Prognosis	Expression of LYL1 is associated with unfavorable prognosis in T-ALL cases. LYL1(+) cases have a gene expression signature corresponding to that of the most immature normal T-cell precursors (CD4/CD8 double-negative cells), which express CD34 but not CD4, CD8, or CD3. Less favorable outcomes were observed in subgroups defined by gene expression profiles characteristic of TAL1(+) or LYL1(+) samples, which resemble late cortical and early pro-T thymocytes, respectively.
Cytogenetics	The LYL1 gene was originally identified at the breakpoint of the translocation t(7;19)(q35;p13) in cases of T-ALL. It is the LYL1 gene but not protein that is structurally altered following t(7;19), resulting in its head-to-head juxtaposition with the T-cell antigen receptor beta gene (TCR-beta). The translocation resulted in truncation of the LYL1 gene and production of abnormal-sized RNAs, bringing LYL1 gene under the regulatory control of TCR-beta, and thus resulting in its ectopic expression. In addition to the t(7;19)(q35;p13), other translocations are t(1;19)(p34;p13), t(1;19)(p32;p13), t(9;19)(q34;p13), t(9;19)(q32;p13), t(10;19)(q24;p13), t(11;19)(p13;p13), t(15;19)(q22;p13) etc; it is not known if all of the translocations lead to enhanced expression of LYL1.
Hybrid/Mutated Gene	The TCR-beta locus at 7q35 spans 685 kb (64-67 variable genes TRBV, 2 clusters of diversity, joining and constant segments).
Oncogenesis	As discussed above, the LYL1 gene was first identified at t(7;19)(q35;p13) associated T-ALL. However, over-expression of LYL1 has been reported in T-ALL cases without apparent chromosome aberration. LYL1, TAL1 and <a href="#">TAL2</a> constitute a discrete subgroup of helix-loop-helix proteins, each of which can potentially contribute to the development of T-ALL. Specific in vivo association between the bHLH and LIM proteins is implicated in human T cell leukemia. LYL1 can readily form heterodimers with E2A and NF-KappaB1 p105 protein. It is possible that LYL1 may function as a dominant-negative preventing the activation of the tumor suppressors like E2A. Ectopic expression of LYL1 may also be involved in myeloid leukemia.

## External links

### Nomenclature

<a href="#">Hugo</a>	<a href="#">LYL1</a>
<a href="#">GDB</a>	<a href="#">LYL1</a>
<a href="#">Entrez_Gene</a>	<a href="#">LYL1 4066</a> lymphoblastic leukemia derived sequence 1

### Cards

<a href="#">Atlas</a>	<a href="#">LYL1ID51ch19p13</a>
<a href="#">GeneCards</a>	<a href="#">LYL1</a>
<a href="#">Ensembl</a>	<a href="#">LYL1</a>
<a href="#">GenAtlas</a>	<a href="#">LYL1</a>
<a href="#">GeneLynx</a>	<a href="#">LYL1</a>
<a href="#">eGenome</a>	<a href="#">LYL1</a>
<a href="#">euGene</a>	<a href="#">4066</a>

### Genomic and cartography

<a href="#">GoldenPath</a>	<a href="#">LYL1 - 19p13.2 chr19:13070848-13074681 - 19p13.2</a> (hg18-Mar_2006)
<a href="#">Ensembl</a>	<a href="#">LYL1 - 19p13.2 [CytoView]</a>

[NCBI](#) [Genes Cyto](#) [Gene Seq](#) [Map View - NCBI]

[OMIM](#) [Disease map](#) [OMIM]

[HomoloGene](#) [LYL1](#)

#### Gene and transcription

[Genbank](#) [BC002796](#) [ ENTREZ ]

[Genbank](#) [CR626486](#) [ ENTREZ ]

[Genbank](#) [M22637](#) [ ENTREZ ]

[Genbank](#) [M22637](#) [ ENTREZ ]

[RefSeq](#) [NM\\_005583](#) [ SRS ] [NM\\_005583](#) [ ENTREZ ]

[RefSeq](#) [AC\\_000062](#) [ SRS ] [AC\\_000062](#) [ ENTREZ ]

[RefSeq](#) [NC\\_000019](#) [ SRS ] [NC\\_000019](#) [ ENTREZ ]

[RefSeq](#) [NT\\_011295](#) [ SRS ] [NT\\_011295](#) [ ENTREZ ]

[RefSeq](#) [NW\\_927195](#) [ SRS ] [NW\\_927195](#) [ ENTREZ ]

[AceView](#) [LYL1](#) AceView - NCBI

[Unigene](#) [Hs.46446](#) [ SRS ] [Hs.46446](#) [ NCBI ] [HS46446](#) [ spliceNest ]

#### Protein : pattern, domain, 3D structure

[SwissProt](#) [Q5JPI2](#) [ SRS ] [Q5JPI2](#) [ EXPASY ] [Q5JPI2](#) [ INTERPRO ]

[Prosite](#) [PS50011 PROTEIN\\_KINASE\\_DOM](#) [ SRS ] [PS50011 PROTEIN\\_KINASE\\_DOM](#) [ Expasy ]

[Interpro](#) [IPR011009 Kinase\\_like](#) [ SRS ] [IPR011009 Kinase\\_like](#) [ EBI ]

[Interpro](#) [IPR000719 Prot\\_kinase](#) [ SRS ] [IPR000719 Prot\\_kinase](#) [ EBI ]

[CluSTR](#) [Q5JPI2](#)

[Pfam](#) [PF00069 Pkinase](#) [ SRS ] [PF00069 Pkinase](#) [ Sanger ] [pfam00069](#) [ NCBI-CDD ]

[Prodom](#) [PD000001 Prot\\_kinase](#)[INRA-Toulouse]

[Prodom](#) [Q5JPI2 Q5JPI2 HUMAN](#) [ Domain structure ] [Q5JPI2 Q5JPI2 HUMAN](#) [ sequences sharing at least 1 domain ]

[Blocks](#) [Q5JPI2](#)

[HPRD](#) [Q5JPI2](#)

#### Protein Interaction databases

[DIP](#) [Q5JPI2](#)

[IntAct](#) [Q5JPI2](#)

#### Polymorphism : SNP, mutations, diseases

[OMIM](#) [151440](#) [ map ]

[GENECLINICS](#) [151440](#)

[SNP](#) [LYL1](#) [dbSNP-NCBI]

[SNP](#) [NM\\_005583](#) [SNP-NCI]

[SNP](#) [LYL1](#) [GeneSNPs - Utah] [LYL1](#) [HGBASE - SRS]

[HAPMAP](#) [LYL1](#) [HAPMAP]

#### General knowledge

[Family Browser](#) [LYL1](#) [UCSC Family Browser]

[SOURCE](#) [NM\\_005583](#)

[SMD](#) [Hs.46446](#)

<a href="#">SAGE</a>	<a href="#">Hs.46446</a>
<a href="#">GO</a>	<a href="#">DNA binding</a> [Amigo] <a href="#">DNA binding</a>
<a href="#">GO</a>	<a href="#">nucleus</a> [Amigo] <a href="#">nucleus</a>
<a href="#">GO</a>	<a href="#">regulation of transcription, DNA-dependent</a> [Amigo] <a href="#">regulation of transcription, DNA-dependent</a>
<a href="#">GO</a>	<a href="#">transcription regulator activity</a> [Amigo] <a href="#">transcription regulator activity</a>
<a href="#">PubGene</a>	<a href="#">LYL1</a>
<b>Other databases</b>	
Other database	<a href="http://www.cleanex.isb-sib.ch/cgi-bin/cleanex_query_result.pl?out_format=NICE&amp;Entry_0=HGNC:6734">http://www.cleanex.isb-sib.ch/cgi-bin/cleanex_query_result.pl?out_format=NICE&amp;Entry_0=HGNC:6734</a>
<b>Probes</b>	
<a href="#">Probe</a>	<a href="#">LYL1 Related clones (RZPD - Berlin)</a>
<b>PubMed</b>	
<a href="#">PubMed</a>	<a href="#">11 Pubmed reference(s) in LocusLink</a>

### Bibliography

**Lyl-1, a novel gene altered by chromosomal translocation in T cell leukemia, codes for a protein with a helix-loop-helix DNA binding motif.**

Mellentin JD, Smith SD, Cleary ML.

Cell. 1989; 58 (1), 77-83.

Medline [2752424](#)

**Structure, chromosome mapping, and expression of the mouse Lyl-1 gene.**

Kuo SS, Mellentin JD, Copeland NG, Gilbert DJ, Jenkins NA, Cleary ML.

Oncogene. 1991; 6(6):961-968.

Medline [2067848](#)

**Specific in vivo association between the bHLH and LIM proteins implicated in human T cell leukemia.**

Wadman I, Li J, Bash RO, Forster A, Osada H, Rabbitts TH, Baer R.

EMBO J 1994; 13 (20), 4831-4839.

Medline [7957052](#)

**Helix-loop-helix proteins LYL1 and E2a form heterodimeric complexes with distinctive DNA-binding properties in hematolymphoid cells.**

Miyamoto A, Cui X, Naumovski L, Cleary ML.

Mol. Cell. Biol. 1996; 16 (5), 2394-2401

Medline [8628307](#)

**Physical interaction of the bHLH LYL1 protein and NF-kappaB1 p105.**

Ferrier R, Nougarede R, Doucet S, Kahn-Perles B, Imbert J, Mathieu-Mahul D.

Oncogene. 1999; 18 (4), 995-1005

Medline [10023675](#)

**Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia.**

Ferrando AA, Neuberg DS, Staunton J, Loh ML, Huard C, Raimondi SC, Behm FG, Pui CH, Downing JR, Gilliland DG, Lander ES, Golub TR, Look AT.

Cancer Cell. 2002; 1(1):75-87.

Medline [12086890](#)

**Gene expression profiling in T-cell acute lymphoblastic leukemia.**

Ferrando AA, Look AT.  
Semin Hematol. 2003; 40(4):274-280.  
Medline [14582078](#)

**Age-related phenotypic and oncogenic differences in T-cell acute lymphoblastic leukemias may reflect thymic atrophy.**

Asnafi V, Beldjord K, Libura M, Villarese P, Millien C, Ballerini P, Kuhlein E, Lafage-Pochitaloff M, Delabesse E, Bernard O, Macintyre E.  
Blood 2004; 104(13):4173-4180.  
Medline [15054041](#)

**Biallelic transcriptional activation of oncogenic transcription factors in T-cell acute lymphoblastic leukemia.**

Ferrando AA, Herblot S, Palomero T, Hansen M, Hoang T, Fox EA, Look AT.  
Blood. 2004; 103(5):1909-1911.  
Medline [14604958](#)

**Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia.**

Ferrando AA, Neuberg DS, Dodge RK, Paietta E, Larson RA, Wiernik PH, Rowe JM, Caligiuri MA, Bloomfield CD, Look AT.  
Lancet. 2004; 363(9408):535-536.  
Medline [14975618](#)

**Oncogenic potential of the transcription factor LYL1 in acute myeloblastic leukemia.**

Meng YS, Khoury H, Dick JE, Minden MD.  
Leukemia. 2005; 19 (11):1941-1947.  
Medline [16094422](#)

**The SCL relative LYL-1 is required for fetal and adult hematopoietic stem cell function and B-cell differentiation.**

Capron C, Lecluse Y, Kaushik AL, Foudi A, Lacout C, Sekkai D, Godin I, Albagli O, Poullion I, Svinartchouk F, Schanze E, Vainchenker W, Sablitzky F, Bennaceur-Griscelli A, Dumenil D.  
Blood. 2006; 107(12):4678-4686.  
Medline [16514064](#)

**The paralogous haemopoietic regulators Lyl1 and SCL are co-regulated by Ets and GATA factors yet Lyl1 cannot rescue the early SCL-/- phenotype.**

Chan WY, Follows GA, Lacaud G, Pimanda JE, Landry JR, Kinston S, Knezevic K, Piltz S, Donaldson IJ, Gambardella L, Sablitzky F, Green AR, Kouskoff V, Gottgens B.  
Blood. 2006 Oct 19; Epub ahead of print  
Medline [17053063](#)

[REVIEW articles](#) *automatic search in PubMed*

[Last year publications](#) *automatic search in PubMed*

[BiblioGene - INIST](#)

[Search in all EBI](#)

**Contributor(s)**

**Written** 12-2006 Yuesheng Meng, Mark D. Minden

**Citation**

*This paper should be referenced as such :*

**Meng Y, Minden MD** . LYL1 (lymphoblastic leukemia derived sequence 1). Atlas Genet Cytogenet Oncol Haematol. December 2006 .  
URL : <http://AtlasGeneticsOncology.org/Genes/LYL1ID51ch19p13.html>

© *Atlas of Genetics and Cytogenetics in Oncology and Haematology*

---